




PHARMACEUTICAL 2022

GRI BIO Inc.
Rank 358 of 466





PHARMACEUTICAL 2022

GRI BIO Inc.
Rank 358 of 466

The relative strengths and weaknesses of GRI BIO Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GRI BIO Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 23% points. The greatest weakness of GRI BIO Inc. is the variable Net Income, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 13%, being 65% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	8,129
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,445
Liabilities, Non-Current	72
Other Assets	206
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-44
Other Revenues	0
Property and Equipment	0
Research and Development	5,187
Selling, General and Administrative Expense	4,072

Output Variable	Value in 1000 USD
Assets	8,335
Liabilities	2,517
Expenses	9,259
Revenues	0
Stockholders Equity	5,818
Net Income	-9,303
Comprehensive Net Income	-9,304
Economic Capital Ratio	13%